These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 23369368

  • 1. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.
    Sitole M, Silva M, Spooner L, Comee MK, Malloy M.
    Clin Ther; 2013 Feb; 35(2):190-7. PubMed ID: 23369368
    [Abstract] [Full Text] [Related]

  • 2. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP, Markova AA, Calle Serrano B, Cornberg M.
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [Abstract] [Full Text] [Related]

  • 3. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Feb; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 4. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
    Cooper C, Lester R, Thorlund K, Druyts E, El Khoury AC, Yaya S, Mills EJ.
    QJM; 2013 Feb; 106(2):153-63. PubMed ID: 23159839
    [Abstract] [Full Text] [Related]

  • 5. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A, Serfaty L.
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [Abstract] [Full Text] [Related]

  • 6. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Shiffman ML, Esteban R.
    Liver Int; 2012 Feb; 32 Suppl 1():54-60. PubMed ID: 22212573
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F, CUPIC Study Group.
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
    Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA.
    PLoS One; 2016 Sep; 11(1):e0145409. PubMed ID: 26752189
    [Abstract] [Full Text] [Related]

  • 12. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF.
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [Abstract] [Full Text] [Related]

  • 16. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ.
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM, French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group.
    Clin Infect Dis; 2014 Dec 15; 59(12):1768-76. PubMed ID: 25139963
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.